Crexont (IPX203) vs Levodopa (Inbrija)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Crexont (IPX203)

Marketed by Amneal Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT03670953 · Phase 3 · completed

The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).

Next expected readout: February 2027 · NCT07138560 (registry estimate)

Reported efficacy

Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)

Result source: NCT03670953

Levodopa (Inbrija)

Marketed by Merz Therapeutics and partners

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT02240030 · Phase 3 · completed

This randomized, double-blind, placebo-controlled phase 3 trial assigned 351 participants to CVT-301 60 mg, CVT-301 84 mg or placebo. Its clinical primary endpoint, the change in UPDRS motor score from predose to 30 minutes post-dose at week 12 for 84 mg versus placebo, was met: -9.83 versus -5.91, a difference of -3.92 points (95% CI -6.84 to -1.00; p=0.0088), as reported in the peer-reviewed publication.

Reported efficacy

Unified Parkinson's Disease Rating Scale (UPDRS) Part III (30 minutes post-dose at week 12): UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019) (met)

Result source: NCT02240030

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCrexont (IPX203)Levodopa (Inbrija)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported-9.8 vs -5.9−3.9 vs placebowk 12 · n 114NCT02240030
4 other results
  • -8.5 vs -6.5 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -9.0 vs -6.5 wk 12 · n 114 · Phase 3 · secondary NCT02240030
  • -5.2 vs -4.2 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -6.5 vs -4.2 wk 12 · n 114 · Phase 3 · secondary NCT02240030
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Crexont (IPX203)
—Not reported
Levodopa (Inbrija)
—Not reported

ON time without troublesome dyskinesia, change

Crexont (IPX203)
—Not reported
Levodopa (Inbrija)
—Not reported

UPDRS Part III, change

Crexont (IPX203)
—Not reported
Levodopa (Inbrija)
-9.8 vs -5.9−3.9 vs placebowk 12 · n 114NCT02240030
4 other results
  • -8.5 vs -6.5 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -9.0 vs -6.5 wk 12 · n 114 · Phase 3 · secondary NCT02240030
  • -5.2 vs -4.2 wk 12 · n 113 · Phase 3 · secondary NCT02240030
  • -6.5 vs -4.2 wk 12 · n 114 · Phase 3 · secondary NCT02240030

MDS-UPDRS Part II, change

Crexont (IPX203)
—Not reported
Levodopa (Inbrija)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Crexont (IPX203): 2 of 4 rows · Levodopa (Inbrija): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCrexont (IPX203)Levodopa (Inbrija)
Dropout rate
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
14.9%CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
15%CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
28.7%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
38.5%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.5%
NCT02352363 · Phase 3 · monotherapy
Discontinued due to AEs
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
—CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
9.1%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.1%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—
NCT02352363 · Phase 3 · monotherapy
Serious AEs
2%IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.1%IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.8%CVT-301 High Dosea
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
5.3%CVT-301 Low Dose
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.2%HIgh Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
14.4%Low Dose
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
15.5%
NCT02352363 · Phase 3 · monotherapy
Most frequent reported AEs
dyskinesia 6.8%
nausea 4.9%
dry mouth 4.2%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
nausea 4.3%
anxiety 2.7%
dizziness 2.3%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
a
cough 14.9% (placebo 1.8%)
upper respiratory tract 6.1% (placebo 2.7%)
nausea 5.3% (placebo 2.7%)
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
cough 15% (placebo 1.8%)
throat irritation 7.1% (placebo 0%)
dyskinesia 4.4% (placebo 0%)
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
HIgh Dose
cough 14.5%
fall 10.7%
upper respiratory tract infection 7.5%
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Low Dose
cough 16.3%
fall 15.7%
upper respiratory tract infection 6.5%
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
cough 13.3%
fall 8.1%
nasopharyngitis 6.6%
NCT02352363 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Crexont (IPX203)

Good on" Time -0.39 vs -0.97 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF-time 0.29 vs 0.76 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PGI-C 29.7% (n=256) vs 18.8% (n=250) IR CD-LD @ 20wk
responder rate · % of participants
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III 1.1 vs 0.9 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part II III 2 vs 1.8 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Levodopa (Inbrija)

UPDRS Part III -9.83 vs -5.91 placebo score @ 12wk
absolute change · score
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 4 more results
-8.47 vs -6.49 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-9.04 vs -6.49 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-5.16 vs -4.18 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-6.45 vs -4.18 placebo score @ 12wk
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF to ON Resolution 60 Min 48.7% (n=113) vs 31.3% (n=112) placebo @ 12wk
event count · % of participants
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 55 Participants as posted
show 1 more result
49.1% (n=114) vs 31.3% (n=112) placebo @ 12wk*
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 56 Participants as posted
PGIC Improvement 54% (n=113) vs 40.2% (n=112) placebo @ 12wk
event count · % of participants
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 61 Participants as posted
show 1 more result
61.4% (n=114) vs 40.2% (n=112) placebo @ 12wk*
NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 70 Participants as posted
OFF to ON 60 Min 54.2% (n=144) @ 52wkDL1
responder rate · % of participants
No placebo or comparator arm
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 78 Participants as posted
show 1 more result
60.1% (n=153) @ 52wk*DL2
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 · converted to % from 92 Participants as posted
OFF Time -0.33 hours @ 4wkDL1
absolute change · hours
No placebo or comparator arm
TV2 (Week 4)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.55 hours @ 4wkDL2
TV2 (Week 4)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.23 hours @ 12wkDL1
absolute change · hours
No placebo or comparator arm
TV3 (Week 12)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.38 hours @ 12wkDL2
TV3 (Week 12)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.65 hours @ 24wkDL1
absolute change · hours
No placebo or comparator arm
TV4 (Week 24)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.73 hours @ 24wkDL2
TV4 (Week 24)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.49 hours @ 36wkDL1
absolute change · hours
No placebo or comparator arm
TV5 (Week 36)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.92 hours @ 36wkDL2
TV5 (Week 36)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.7 hours @ 52wkDL1
absolute change · hours
No placebo or comparator arm
TV6 (Week 52)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-0.88 hours @ 52wkDL2
TV6 (Week 52)
NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Levodopa (Inbrija)'s landscape